Paroxysmal supraventricular tachycardia (PSVT) is a type of supraventricular tachycardia. Often people have no symptoms. Otherwise symptoms may include palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain. Episodes start and end suddenly.
About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. Problems typically begin in those 12 to 45 years old. Women are more often affected than men. Outcomes in those who otherwise have a normal heart are generally good. An ultrasound of the heart may be done to rule out underlying heart problems.
In 2018, the global Paroxysmal Supraventricular Tachycardia market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Paroxysmal Supraventricular Tachycardia status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Paroxysmal Supraventricular Tachycardia development in United States, Europe and China.
The key players covered in this study
Teva Pharmaceutical Industries
St. Jude Medical
Market segment by Type, the product can be split into
AV Nodal Re-Entrant Tachycardia (AVNRT)
AV Reciprocating Tachycardia (AVRT)
Paroxysmal Atrial Tachycardia (PAT)
Wolff-Parkinson-White Syndrome (WPW)
Market segment by Application, split into
Hospitals & Clinics
Medical Research Centers
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Paroxysmal Supraventricular Tachycardia status, future forecast, growth opportunity, key market and key players.
To present the Paroxysmal Supraventricular Tachycardia development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Paroxysmal Supraventricular Tachycardia are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.